Serological diagnosis of Toxoplasma gondii infection
| Autor: | Luc Paris, C. L’Ollivier, Ermanno Candolfi, Hervé Pelloux, Sandrine Houzé, Hélène Fricker-Hidalgo, Isabelle Villena, B. Cimon, N. Godineau, Odile Villard |
|---|---|
| Přispěvatelé: | Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] (LAPM), Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Hôpital Delafontaine, Centre Hospitalier de Saint-Denis [Ile-de-France], Services de Maladies Infectieuses et Tropicales [CHU Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Ressources Biologiques Toxoplasmes, Centre National de référence de la Toxoplasmose (CNRT) |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Microbiology (medical) Pediatrics medicine.medical_specialty Igm antibody 030106 microbiology Severe disease Context (language use) Disease Serology 03 medical and health sciences medicine [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ComputingMilieux_MISCELLANEOUS biology business.industry Toxoplasma gondii General Medicine biology.organism_classification medicine.disease Toxoplasmosis 3. Good health [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology Infectious Diseases Immunization Immunology business |
| Zdroj: | Diagnostic Microbiology and Infectious Disease Diagnostic Microbiology and Infectious Disease, Elsevier, 2016, 84 (1), pp.22-33. ⟨10.1016/j.diagmicrobio.2015.09.009⟩ |
| ISSN: | 0732-8893 |
| DOI: | 10.1016/j.diagmicrobio.2015.09.009 |
| Popis: | Toxoplasmosis manifests no clinical signs in 80% of cases in immunocompetent patient, causing immunization characterized by the persistence of cysts, particularly in brain, muscles, and retina. Assessing the serological status, based on testing for serum toxoplasma IgG and IgM antibodies, is essential in cases that are increasingly at risk for the more severe disease forms, such as congenital or ocular toxoplasmosis. This disease also exposes immunosuppressed patients to reactivation, which can lead to more widespread forms and increased mortality. By interpreting the serological results, we can estimate the risk of contamination or reactivation and define appropriate prophylactic and preventive measures, such as hygienic and dietetic, therapeutic, biological, and clinical follow-up, according to the clinical context. We hereby propose practical approaches based on serological data, resulting from a consensus of a group of experts from the French National Reference Center Network for Toxoplasmosis, according to both routine and specific clinical situations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect